Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | TYMP | P19971 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31240217 | 1.00 | ALDH1A1 (0.42) | ALDH1A1HDAC6CNR1TYMPMTNR1A | |
| SCHEMBL31240154 | 1.00 | ALDH1A1 (0.42) | ALDH1A1HDAC6CNR1TYMPMTNR1A | |
| SCHEMBL31240234 | 0.92 | TYMP (0.39) | ALDH1A1HDAC6TYMP | |
| SCHEMBL31240199 | 0.80 | ALDH1A1 (0.35) | ALDH1A1HDAC6CNR1MTNR1A | |
| SCHEMBL31240156 | 0.80 | ALDH1A1 (0.35) | ALDH1A1HDAC6CNR1MTNR1A | |
| SCHEMBL30271284 | 0.80 | TYMP (0.45) | TYMP | |
| SCHEMBL30271283 | 0.80 | LMNA (0.42) | ALDH1A1 | |
| SCHEMBL30271273 | 0.80 | LMNA (0.42) | ALDH1A1 | |
| SCHEMBL13551205 | 0.77 | ALDH1A1 (0.54) | ALDH1A1HDAC6CNR1 | |
| SCHEMBL30271280 | 0.76 | TYMP (0.42) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705312-A1 | LIPID-BASED CONJUGATES FOR SYSTEMIC, CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, AND OCULAR DELIVERY | Sanegene Bio USA Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250018045-A1 | LIPID-BASED CONJUGATES FOR SYSTEMIC, CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, AND OCULAR DELIVERY | SANEGENE BIO USA INC. | 2025-01-16 | — | — | US | disclosed |
| WO-2024229397-A1 | LIPID-BASED CONJUGATES FOR SYSTEMIC, CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, AND OCULAR DELIVERY | SANEGENE BIO USA INC. (US) | 2024-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018045-A1 | LIPID-BASED CONJUGATES FOR SYSTEMIC, CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, AND OCULAR DELIVERY | FABP7, PMP22, LPAR6 | ALDH1A1 1131/4885HDAC6 466/4885CNR1 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.